The New Alzheimer’s Drug: What is Leqembi?

The premier episode of Zoom in on Dementia & Alzheimer's focused on Leqembi, a new anti-amyloid treatment for Alzheimer's disease that received conditional approval from the FDA in January 2023.
Dr. Sharon Cohen, neurologist and medical director at Toronto Memory Program, and host Nancy Lynn discussed the drug's benefits, availability, potential side effects, cost, and more, as well as other drugs in development for Alzheimer's.
Learn more: BrightFocus.org/ADZoom.
For information and free dementia and Alzheimer's disease resources, call BrightFocus Foundation at 1-800-437-2423 to speak with one of our staff members.
#dementia #alzheimers #alzheimer #alzheimersdisease #leqembi #alzheimersawareness

[@alexlex5792]

Leqembi finally gives time for the ill ❤. Much hope 🎉

[@sarahdisandro9306]

Such valuable information for people living with Alzheimer's disease and their families. Looking forward to future episodes!

[@BrightfocusOrg]

Thank you!

[@PieterCoetzee-zl7ms]

From South Africa

[@crem8me]

I am in a study involving lecanemab based out of Summit Research in Portland Oregon. I am now doing subcutaneous every week at home after a year plus of infusions at Summit.

[@rudylampas2279]

Lord thank you so much. We are no longer hopeless and helpless.

[@celestinai5475]

Nice getting these informations.

[@BrightfocusOrg]

Thank you. We are glad that you found this episode helpful.

[@vinitawadhwa2206]

My wife has been diagnosed with Lowe body dementia, will this medicine be help full pl advice , we r from India

[@BrightfocusOrg]

Thank you for your question! Leqembi received full approval from the U.S. Food and Drug Administration on July 6, 2023. It is an antibody that works to clear the brain of an abnormal protein called amyloid, known to be one of the root causes of Alzheimer’s. It’s intended for people who have mild cognitive impairment or mild dementia and are shown to have amyloid present in their brains. To learn more, please visit www.brightfocus.org/alzheimers/article/facts-about-leqembi-new-alzheimers-drug.

[@patriciaroberts491]

Is there a possibility of a person getting in to receive this new drug & help in the researching this drug?

[@BrightfocusOrg]

Thank you for your question. Leqembi received full approval from the FDA on July 6, 2023. It is an antibody that works to clear the brain of an abnormal protein called amyloid, known to be one of the root causes of Alzheimer’s. It’s intended for people who have mild cognitive impairment or mild dementia and are shown to have amyloid present in their brains.
Please talk to your healthcare provider if you have questions or concerns about Leqembi. For more information about Leqembi, please visit bit.ly/3reLPOn.

[@petermorla3250]

Can lequimbi be put into a pill form?

[@BrightfocusOrg]

Leqembi is not available in pill form. Leqembi is given through IV infusion every two weeks. It is available at certain infusion centers across the U.S. Each infusion lasts about an hour. Leqembi is given through IV infusion so that it more easily gets to the brain.
Please talk to your healthcare provider if you have questions or concerns about Leqembi. For more information about Leqembi, please visit bit.ly/3reLPOn.